Biogen

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
9,610
Employees9,610
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
9,610
Employees9,610

BIIB Key Statistics

Market cap
42.02B
Market cap42.02B
Price-Earnings ratio
14.89
Price-Earnings ratio14.89
Dividend yield
Dividend yield
Average volume
1.02M
Average volume1.02M
High today
$293.01
High today$293.01
Low today
$289.67
Low today$289.67
Open price
$292.34
Open price$292.34
Volume
557.32K
Volume557.32K
52 Week high
$311.88
52 Week high$311.88
52 Week low
$187.16
52 Week low$187.16

BIIB News

Reuters 2h
UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

(Adds background) Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketi...

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen
Yahoo Finance 3h
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European ... - Yahoo Finance

Biogen Inc. TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nas...

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European ... - Yahoo Finance
Reuters 6d
Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - Reuters

Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the marke...

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - Reuters

Analyst ratings

64%

of 33 ratings
Buy
63.6%
Hold
36.4%
Sell
0%

BIIB Earnings

$0.00
$1.89
$3.79
$5.68
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
$3.48 per share
Estimated$3.48 per share
Actual
Available Feb 15, Pre-Market
ActualAvailable Feb 15, Pre-Market

More BIIB News

Investor's Business Daily 6d
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug

Eli Lilly (LLY) stock dipped Friday after the Food and Drug Administration unexpectedly rejected its request for an accelerated approval of its Alzheimer's trea...

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.